Greenleaf Trust Decreases Holdings in Stryker Corporation $SYK

Greenleaf Trust trimmed its position in Stryker Corporation (NYSE:SYK) by 0.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 16,564,209 shares of the medical technology company’s stock after selling 79,279 shares during the quarter. Stryker makes up 53.4% of Greenleaf Trust’s portfolio, making the stock its biggest position. Greenleaf Trust’s holdings in Stryker were worth $5,821,823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the company. Palumbo Wealth Management LLC bought a new position in Stryker in the fourth quarter valued at approximately $212,000. Perfromance Wealth Partners LLC bought a new position in Stryker in the fourth quarter valued at approximately $284,000. Snider Financial Group increased its stake in Stryker by 26.3% in the fourth quarter. Snider Financial Group now owns 16,370 shares of the medical technology company’s stock valued at $5,753,000 after acquiring an additional 3,411 shares during the last quarter. Pacific Point Advisors LLC bought a new position in Stryker in the fourth quarter valued at approximately $1,177,000. Finally, MBL Wealth LLC increased its stake in Stryker by 64.0% in the fourth quarter. MBL Wealth LLC now owns 1,701 shares of the medical technology company’s stock valued at $598,000 after acquiring an additional 664 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE SYK opened at $331.64 on Wednesday. The firm’s fifty day moving average price is $356.14 and its two-hundred day moving average price is $361.12. The stock has a market cap of $127.01 billion, a PE ratio of 39.48, a PEG ratio of 1.94 and a beta of 0.92. Stryker Corporation has a fifty-two week low of $319.32 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the previous year, the firm posted $4.01 earnings per share. The company’s revenue was up 11.4% on a year-over-year basis. On average, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 41.90%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SYK. TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research note on Monday, January 26th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a research note on Tuesday, January 6th. Evercore set a $390.00 target price on shares of Stryker in a research note on Monday, January 5th. Barclays reaffirmed an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Finally, Robert W. Baird set a $437.00 target price on shares of Stryker in a research note on Friday, January 30th. Fourteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $425.56.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.